Message from the CEO

Founded in 1950, Fujirebio entered the clinical diagnostics business in 1966. Guided by our mission to create new value in healthcare and so contribute to human health and the future of medical care more widely, we have grown as a global diagnostics company delivering innovative diagnostic solutions to healthcare professionals and partners worldwide.

As part of the H.U. Group, Fujirebio operates a truly global business structure spanning Japan, the United States, Europe and beyond. Across therapeutic areas including oncology, infectious diseases, and neurological disorders, we have consistently focused on researching, developing, and manufacturing high quality diagnostic assays that create new clinical value and support better medical decision making.

Our portfolio includes the fully automated chemiluminescent immunoassay platform, Lumipulse, as well as the rapid diagnostic test series, ESPLINE.

The assays we develop are delivered to clinical settings in Japan and around the world through these proprietary platforms. This means we can prove their performance and clinical value in real-world practice.

Alongside this, we have expanded and embedded our well established Contract Development and Manufacturing Organization (CDMO) business model.

Today, Fujirebio’s technologies, biomarkers and raw materials discreetly support diagnostic platforms across the globe, helping bring innovative diagnostics to patients worldwide through trusted partnerships.

By validating the value, we create on our own platforms and sharing it through strategic partnerships, we aim to ensure that breakthrough diagnostics reach clinical laboratories more broadly, more quickly, and with maximum impact.

As an innovator in the field of in vitro diagnostics, Fujirebio will continue to create new value in healthcare—contributing to human health and shaping the future of medical care through innovation without borders and partnerships without limits.

Tadashi Ninomiya, President & CEO of Fujirebio Holdings, Inc.